Company Overview: PRTK

Upcoming Projects (PRTK)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (PRTK)

Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (PRTK)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (PRTK)

Allergran (AGN) and Paratek (PRTK) expecting approval for Sarecycline, an antibiotic designed to treat inflammatory acne
Tickers: AGN, PRTK
Occurred on: Oct 03, 2018
Ad Com Review of Paratek Pharma's (PRTK) Omadacycline NDA briefing documents released
Ticker: PRTK
Occurred on: Aug 06, 2018
Paratek (PRTK) Plans to Submit New Drug Application in H1 2018 for Omadacycline in Treatment of Community Acquired Bacterial Pneumonia (CABP)
Ticker: PRTK
Occurred on: Jan 03, 2018
Allergran (AGN) and Paratek (PRTK) set to file NDA for Sarecycline, an antibiotic designed to treat inflammatory acne, in 2H 2017
Tickers: AGN, PRTK
Occurred on: Dec 20, 2017
Paratek (PRTK) Expects Top-Line Data in Q2 2017 for Phase 3 Trial Evaluating oral Omadacycline in Treatment of Acute Bacterial Skin and Skin Structural Infections (ABSSI)
Ticker: PRTK
Occurred on: Jun 03, 2017
Paratek (PRTK) Phase 1 Data Evaluating Omadacycline in Penetrating Lung Tissue and Epithelial Lining Fluid
Ticker: PRTK
Occurred on: Apr 25, 2017
Paratek (PRTK) Expects Top-Line Data in Q2 for Phase 3 Trial Evaluating Omadacycline in Treatment of Community Acquired Bacterial Pneumonia (CABP)
Ticker: PRTK
Occurred on: Apr 03, 2017
Phase 3 data of Sarecycline, a once-daily, oral narrow-spectrum antibiotic with anti-inflammatory properties developed by Paratek (PRTK) in conjunction with Allergan (AGN) for Severe acne vulgaris due Q2 2017
Tickers: PRTK, AGN
Occurred on: Mar 27, 2017
Paratek Announces Completion of Enrollment in Omadacycline Phase 3 Community-Acquired Bacterial Pneumonia Study
Ticker: PRTK
Occurred on: Jan 18, 2017
Paratel (PRTK) Completes Enrollment in Phase 3 Trial Evaluating Omadacycline in Treatment of Community Acquired Bacterial Pneumonia (CABP)
Ticker: PRTK
Occurred on: Jan 18, 2017
Paratek projects its ongoing phase 1b clinical study evaluating omadacycline in the treatment of uncomplicated urinary tract infections (uUTI) will report top-line data in the fourth quarter of 2016
Ticker: PRTK
Occurred on: Nov 02, 2016
Paratek Announces that Omadacycline Met All Primary and Secondary Efficacy Outcomes Designated by FDA and EMA in a Phase 3 Study in Acute Bacterial Skin Infections; Omadacycline was Generally Safe and Well-Tolerated
Ticker: PRTK
Occurred on: Jun 16, 2016
Omadacycline for the treatment of Acute Bacterial Skin and Skin Structure Infections to report top-line data in mid-2016
Ticker: PRTK
Occurred on: Jun 16, 2016

Strategic Initiatives (PRTK)

Don’t see a strategic initiative related to the company you care about? Create your own!

PRTK Overview